Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

291 views

Visitors from

US 53%·

AU 34%·

IN 7%·

GB 2%·

HK 1%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

PacBio Earnings: What To Look For From PACB

February 10, 2026 at 22:04 PM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

PACB Cover Image

Genomics company Pacific Biosciences of California (NASDAQ: PACB) will be announcing earnings results this Thursday after market hours. Here’s what to expect.

PacBio missed analysts’ revenue expectations by 4.5% last quarter, reporting revenues of $38.44 million, down 3.8% year on year. It was a slower quarter for the company, with a significant miss of analysts’ revenue estimates.

Is PacBio a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting PacBio’s revenue to grow 9.7% year on year to $43.04 million, a reversal from the 32.8% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.13 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. PacBio has missed Wall Street’s revenue estimates five times over the last two years.

Looking at PacBio’s peers in the life sciences tools & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Illumina delivered year-on-year revenue growth of 5%, beating analysts’ expectations by 3.2%, and Medpace reported revenues up 32%, topping estimates by 3.3%. Illumina traded down 10.4% following the results while Medpace was also down 16.1%.

Read our full analysis of Illumina’s results here and Medpace’s results here.

Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the life sciences tools & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. PacBio is down 9.9% during the same time and is heading into earnings with an average analyst price target of $2.42 (compared to the current share price of $1.82).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article